Q2 sales were primarily driven by favourable FX developments (+10pp) whereas organic growth contributed 2pp to the +14% total growth rate to €3,220m. Gross profit declined from 70.1% to 68.5% but EBITDA improved +10% to €845m. Net profit attributable to shareholders rose +13% to €343m. Operating CF does not reflect the good operating performance (-24% to €326m) due to significantly higher NWC (€-365m after €-193m), primarily burdened by clearly higher changes in
06 Aug 2015
Rebif in trouble and Ebitux’s loses dynamics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rebif in trouble and Ebitux’s loses dynamics
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
06 Aug 2015 -
Author:
Martin Schnee -
Pages:
3
Q2 sales were primarily driven by favourable FX developments (+10pp) whereas organic growth contributed 2pp to the +14% total growth rate to €3,220m. Gross profit declined from 70.1% to 68.5% but EBITDA improved +10% to €845m. Net profit attributable to shareholders rose +13% to €343m. Operating CF does not reflect the good operating performance (-24% to €326m) due to significantly higher NWC (€-365m after €-193m), primarily burdened by clearly higher changes in